Promitil

DRUG4 trials

Sponsors

Lipomedix Pharmaceuticals Inc.

Conditions

CancerCancer of OvaryGastro-Intestinal Intraepithelial NeoplasiaMetastatic Colorectal Cancer (mCRC)Metastatic DiseasePancreatic Ductal AdenocarcinomaSolid Tumor

Phase 1

Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.

CompletedNCT01705002

Lipomedix Pharmaceuticals Inc.Cancer, Metastatic Colorectal Cancer (mCRC), Solid Tumor

Start: 2012-10-31End: 2018-06-30Updated: 2018-07-10

Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients

CompletedNCT03823989

Lipomedix Pharmaceuticals Inc.Cancer, Metastatic Disease, Solid Tumor

Start: 2019-01-03End: 2021-12-30Updated: 2022-01-06

Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

TerminatedNCT04729205

Lipomedix Pharmaceuticals Inc.Cancer, Gastro-Intestinal Intraepithelial Neoplasia

Start: 2021-01-13End: 2023-09-12Updated: 2023-09-14

Phase 2

Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy

TerminatedNCT06478862

Lipomedix Pharmaceuticals Inc.Cancer of Ovary, Pancreatic Ductal Adenocarcinoma

Start: 2024-06-13End: 2026-01-02Updated: 2026-01-09